Reduction in promotor methylation utilizing EGCG (Epigallocatechin-3-gallate) restores RXRα expression in human colon cancer cells

Oncotarget

Volumn 7, Issue 23, 2016, Pages 35313-35326

  Morris, Jay ^a   Moseley, Vondina R ^b   Cabang, April B ^a   Coleman, Katie ^b   Wei, Wei ^b   Garrett Mayer, Elizabeth ^c   Wargovich, Michael J ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Colon cancer; EGCG; Epigenetics; Methylation; RXR

Indexed keywords

BETA CATENIN; DECITABINE; EPIGALLOCATECHIN GALLATE; RETINOID X RECEPTOR ALPHA; ANTINEOPLASTIC AGENT; CATECHIN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER PREVENTION; CANCER RISK; CELL CYCLE PROGRESSION; CELL VIABILITY; CHEMOPROPHYLAXIS; COLON CANCER; COLON CARCINOGENESIS; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK REDUCTION; TISSUE MICROARRAY; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; COLON TUMOR; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TEA; TUMOR CELL LINE;

ANTICARCINOGENIC AGENTS; CATECHIN; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROMOTER REGIONS, GENETIC; RETINOID X RECEPTOR ALPHA; TEA;

EID: 84973664388     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9204     Document Type: Article

References (56)

1. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674
2. Ferguson LR, Tatham AL, Lin Z and Denny WA. Epigenetic regulation of gene expression as an anticancer drug target. Current cancer drug targets. 2011; 11:199-212
3. Chik F, Szyf M and Rabbani SA. Role of epigenetics in cancer initiation and progression. Advances in experimental medicine and biology. 2011; 720:91-104
4. Rajendran P, Ho E, Williams DE and Dashwood RH. Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells. Clinical epigenetics. 2011; 3:4
5. Miremadi A, Oestergaard MZ, Pharoah PD and Caldas C. Cancer genetics of epigenetic genes. Human molecular genetics. 2007; 16 Spec No 1:R28-49
6. Schnekenburger M and Diederich M. Epigenetics Offer New Horizons for Colorectal Cancer Prevention. Current colorectal cancer reports. 2012; 8:66-81
7. Vanden Berghe W. Epigenetic impact of dietary polyphenols in cancer chemoprevention: Lifelong remodeling of our epigenomes. Pharmacological research. 2012
8. Hardy TM and Tollefsbol TO. Epigenetic diet: impact on the epigenome and cancer. Epigenomics. 2011; 3:503-518
9. Huang J, Plass C and Gerhauser C. Cancer chemoprevention by targeting the epigenome. Current drug targets. 2011; 12:1925-1956
10. Papoutsis AJ, Borg JL, Selmin OI and Romagnolo DF. BRCA-1 promoter hypermethylation and silencing induced by the aromatic hydrocarbon receptor-ligand TCDD are prevented by resveratrol in MCF-7 Cells. The Journal of nutritional biochemistry. 2011
11. Suzuki Y, Miyoshi N and Isemura M. Health-promoting effects of green tea. Proceedings of the Japan Academy Series B, Physical and biological sciences. 2012; 88:88-101
12. Hardtner C, Multhoff G, Falk W and Radons J. (-)-Epigallocatechin-3-gallate, a green tea-derived catechin, synergizes with celecoxib to inhibit IL-1-induced tumorigenic mediators by human pancreatic adenocarcinoma cells Colo357. European journal of pharmacology. 2012
13. Volate SR, Muga SJ, Issa AY, Nitcheva D, Smith T and Wargovich MJ. Epigenetic modulation of the retinoid X receptor alpha by green tea in the azoxymethane-Apc Min/+ mouse model of intestinal cancer. Molecular carcinogenesis. 2009; 48:920-933
14. Zhu Z, Wang Y, Liu Z, Wang F and Zhao Q. Inhibitory effects of epigallocatechin-3-gallate on cell proliferation and the expression of HIF-1alpha and P-gp in the human pancreatic carcinoma cell line PANC-1. Oncology reports. 2012; 27:1567-1572
15. Wang H, Bian S and Yang CS. Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1alpha. Carcinogenesis. 2011; 32:1881-1889
16. Zhu BH, He YL, Zhan WH, Cai SR, Wang Z, Zhang CH and Chen HY. [(-)-Epigallocatechin-3-gallate reduces vascular endothelial growth factor expression in gastric cancer cells via suppressing activity]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery. 2011; 14:631-635
17. Singh BN, Shankar S and Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochemical pharmacology. 2011; 82:1807-1821
18. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W and Yang CS. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer research. 2003; 63:7563-7570
19. Lee WJ, Shim JY and Zhu BT. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Molecular pharmacology. 2005; 68:1018-1030
20. Yang XW, Wang XL, Cao LQ, Jiang XF, Peng HP, Lin SM, Xue P and Chen D. Green tea polyphenol epigallocatechin-3-gallate enhances 5-fluorouracil-induced cell growth inhibition of hepatocellular carcinoma cells. Hepatology research. 2012; 42:494-501
21. Shimizu M, Sakai H, Shirakami Y, Yasuda Y, Kubota M, Terakura D, Baba A, Ohno T, Hara Y, Tanaka T and Moriwaki H. Preventive effects of (-)-epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db Mice. Cancer Prev Res (Phila). 2011; 4:396-403
22. Hsu YC and Liou YM. The anti-cancer effects of (-)-epigallocatechin-3-gallate on the signaling pathways associated with membrane receptors in MCF-7 cells. Journal of cellular physiology. 2011; 226:2721-2730
23. Deng YT and Lin JK. EGCG inhibits the invasion of highly invasive CL1-5 lung cancer cells through suppressing MMP-2 expression via JNK signaling and induces G2/M arrest. Journal of agricultural and food chemistry. 2011; 59:13318-13327
24. Meeran SM, Patel SN, Chan TH and Tollefsbol TO. A novel prodrug of epigallocatechin-3-gallate: differential epigenetic hTERT repression in human breast cancer cells. Cancer Prev Res (Phila). 2011; 4:1243-1254
25. Jacobs ET, Martinez ME, Campbell PT, Conti DV, Duggan D, Figueiredo JC, Haile RW, LeRoy EC, Poynter JN, Thompson PA and Baron JA. Genetic variation in the retinoid X receptor and calcium-sensing receptor and risk of colorectal cancer in the Colon Cancer Family Registry. Carcinogenesis. 2010; 31:1412-1416
26. Egan JB, Thompson PA, Ashbeck EL, Conti DV, Duggan D, Hibler E, Jurutka PW, Leroy EC, Martinez ME, Mount D and Jacobs ET. Genetic polymorphisms in vitamin D receptor VDR/RXRA influence the likelihood of colon adenoma recurrence. Cancer research. 2010; 70:1496-1504
27. Nader N, Ng SS, Wang Y, Abel BS, Chrousos GP and Kino T. Liver x receptors regulate the transcriptional activity of the glucocorticoid receptor: implications for the carbohydrate metabolism. PloS one. 2012; 7:e26751
28. Thorne J and Campbell MJ. The vitamin D receptor in cancer. The Proceedings of the Nutrition Society. 2008; 67:115-127
29. Meyer MB, Goetsch PD and Pike JW. VDR/RXR and TCF4/beta-catenin cistromes in colonic cells of colorectal tumor origin: impact on c-FOS and c-MYC gene expression. Mol Endocrinol. 2012; 26:37-51
30. Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknaes M, Hektoen M, Lind GE and Lothe RA. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis. 2013; 2:e71
31. Hinoue T, Weisenberger DJ, Pan F, Campan M, Kim M, Young J, Whitehall VL, Leggett BA and Laird PW. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PloS one. 2009; 4:e8357
32. Boland CR and Goel A. Somatic evolution of cancer cells. Seminars in cancer biology. 2005; 15:436-450
33. Pino MS and Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010; 138:2059-2072
34. Issa JP. CpG-island methylation in aging and cancer. Current topics in microbiology and immunology. 2000; 249:101-118
35. Bird A. DNA methylation patterns and epigenetic memory. Genes & development. 2002; 16:6-21
36. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB and Issa JP. CpG island methylator phenotype in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96:8681-8686
37. Bae JM, Kim MJ, Kim JH, Koh JM, Cho NY, Kim TY and Kang GH. Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status. Virchows Archiv. 2011; 459:55-63
38. Li G, Yin W, Chamberlain R, Hewett-Emmett D, Roberts JN, Yang X, Lippman SM and Clifford JL. Identification and characterization of the human retinoid X receptor alpha gene promoter. Gene. 2006; 372:118-127
39. Moseley VR, Morris J, Knackstedt RW and Wargovich MJ. Green tea polyphenol epigallocatechin 3-gallate, contributes to the degradation of DNMT3A and HDAC3 in HCT 116 human colon cancer cells. Anticancer research. 2013; 33:5325-5333
40. Pinheiro M, Ahlquist T, Danielsen SA, Lind GE, Veiga I, Pinto C, Costa V, Afonso L, Sousa O, Fragoso M, Santos L, Henrique R, Lopes P, Lopes C, Lothe RA and Teixeira MR. Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin. BMC cancer. 2010; 10:587
41. de Sousa EMF, Colak S, Buikhuisen J, Koster J, Cameron K, de Jong JH, Tuynman JB, Prasetyanti PR, Fessler E, van den Bergh SP, Rodermond H, Dekker E, van der Loos CM, Pals ST, van de Vijver MJ, Versteeg R, et al. Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell stem cell. 2011; 9:476-485
42. Hibler EA, Jurutka PW, Egan JB, Hu C, LeRoy EC, Martinez ME, Thompson PA and Jacobs ET. Association between polymorphic variation in VDR and RXRA and circulating levels of vitamin D metabolites. The Journal of steroid biochemistry and molecular biology. 2010; 121:438-441
43. Natrajan MS, de la Fuente AG, Crawford AH, Linehan E, Nunez V, Johnson KR, Wu T, Fitzgerald DC, Ricote M, Bielekova B and Franklin RJ. Retinoid X receptor activation reverses age-related deficiencies in myelin debris phagocytosis and remyelination. Brain. 2015; 138:3581-3597
44. Welch JS, Niu H, Uy GL, Westervelt P, Abboud CN, Vij R, Stockerl-Goldstein KE, Jacoby M, Pusic I, Schroeder MA, Dipersio JF and Cashen AF. A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. Am J Hematol. 2014; 89:E103-108
45. Janakiram NB, Mohammed A, Qian L, Choi CI, Steele VE and Rao CV. Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min/+) mice. Neoplasia. 2012; 14:159-168
46. Lee M-J, Maliakal P, Chen L, Meng X, Bondoc FY, Prabhu S, Lambert G, Mohr S and Yang CS. Pharmacokinetics of Tea Catechins after Ingestion of Green Tea and (-)-Epigallocatechin-3-gallate by Humans: Formation of Different Metabolites and Individual Variability. Cancer Epidemiology Biomarkers & Prevention. 2002; 11:1025-1032
47. Yang CS, Chen L, Lee MJ, Balentine D, Kuo MC and Schantz SP. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiology Biomarkers & Prevention. 1998; 7:351-354
48. Liu S, Wang X, Chen L, Hou L and Zhou T. Aggregation morphologies of a series of heterogemini surfactants with a hydroxyl head group in aqueous solution. Soft Matter. 2014; 10:9177-9186
49. Vu HA, Beppu Y, Chi HT, Sasaki K, Yamamoto H, Xinh PT, Tanii T, Hara Y, Watanabe T, Sato Y and Ohdomari I. Green tea epigallocatechin gallate exhibits anticancer effect in human pancreatic carcinoma cells via the inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor. J Biomed Biotechnol. 2010; 2010:290516
50. Zhang D, Al-Hendy M, Richard-Davis G, Montgomery-Rice V, Rajaratnam V and Al-Hendy A. Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells. Fertil Steril. 2010; 94:1887-1893
51. Zhou L and Elias RJ. Antioxidant and pro-oxidant activity of (-)-epigallocatechin-3-gallate in food emulsions: Influence of pH and phenolic concentration. Food Chem. 2013; 138:1503-1509
52. Gruber PJ, Kubalak SW, Pexieder T, Sucov HM, Evans RM and Chien KR. RXR alpha deficiency confers genetic susceptibility for aortic sac, conotruncal, atrioventricular cushion, and ventricular muscle defects in mice. J Clin Invest. 1996; 98:1332-1343
53. Sucov HM, Dyson E, Gumeringer CL, Price J, Chien KR and Evans RM. RXR alpha mutant mice establish a genetic basis for vitamin A signaling in heart morphogenesis. Genes & development. 1994; 8:1007-1018
54. Sporn MB, Dunlop NM, Newton DL and Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Federation proceedings. 1976; 35:1332-1338
55. Nandakumar V, Vaid M and Katiyar SK. (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. Carcinogenesis. 2011; 32:537-544
56. Larriba MJ, Ordonez-Moran P, Chicote I, Martin-Fernandez G, Puig I, Munoz A and Palmer HG. Vitamin D receptor deficiency enhances Wnt/beta-catenin signaling and tumor burden in colon cancer. PloS one. 2011; 6:e23524